Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (421-430 of 484) with videos related to

Pageof 49
Sort By:
Rheumatology (Oxford, England)|May 5, 2020
Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in sclerodermaBodoor Yaseen, Henry Lopez, Zeinab Taki, et al.
Rheumatology (Oxford, England)|January 13, 2023
A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)Deborah J Griffiths-Jones, Yvonne Sylvestre Garcia, W David Ryder, et al.
Annals of the Rheumatic Diseases|September 14, 2016
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity indexGabriele Valentini, Michele Iudici, Ulrich A Walker, et al.
Annals of the Rheumatic Diseases|September 1, 2010
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trialMarco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, et al.
European Heart Journal. Cardiovascular Imaging|July 1, 2022
Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance studyDaniel S Knight, Nina Karia, Alice R Cole, et al.
Rheumatology (Oxford, England)|January 18, 2015
Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR populationEric Hachulla, Pierre Clerson, Paolo Airò, et al.
Annals of the Rheumatic Diseases|November 26, 2021
Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaireMike O Becker, Rucsandra Dobrota, Alexandru Garaiman, et al.
Expert Review of Clinical Immunology|June 5, 2026
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposiumIvan Foeldvari, Kathryn S Torok, Jens Klotsche, et al.
Journal of Clinical Medicine|October 27, 2022
The Effect of Body Fat Distribution on Systemic SclerosisGonzalo Villanueva-Martin, Marialbert Acosta-Herrera, Martin Kerick, et al.
Annals of the Rheumatic Diseases|June 7, 2021
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypesMarialbert Acosta-Herrera, Martin Kerick, Elena Lopéz-Isac, et al.
Pageof 49

Showing results (421-430 of 484) with videos related to

Sort By:
Pageof 49
Rheumatology (Oxford, England)|May 5, 2020
Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in sclerodermaBodoor Yaseen, Henry Lopez, Zeinab Taki, et al.
Rheumatology (Oxford, England)|January 13, 2023
A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)Deborah J Griffiths-Jones, Yvonne Sylvestre Garcia, W David Ryder, et al.
Annals of the Rheumatic Diseases|September 14, 2016
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity indexGabriele Valentini, Michele Iudici, Ulrich A Walker, et al.
Annals of the Rheumatic Diseases|September 1, 2010
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trialMarco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, et al.
European Heart Journal. Cardiovascular Imaging|July 1, 2022
Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance studyDaniel S Knight, Nina Karia, Alice R Cole, et al.
Rheumatology (Oxford, England)|January 18, 2015
Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR populationEric Hachulla, Pierre Clerson, Paolo Airò, et al.
Annals of the Rheumatic Diseases|November 26, 2021
Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaireMike O Becker, Rucsandra Dobrota, Alexandru Garaiman, et al.
Expert Review of Clinical Immunology|June 5, 2026
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposiumIvan Foeldvari, Kathryn S Torok, Jens Klotsche, et al.
Journal of Clinical Medicine|October 27, 2022
The Effect of Body Fat Distribution on Systemic SclerosisGonzalo Villanueva-Martin, Marialbert Acosta-Herrera, Martin Kerick, et al.
Annals of the Rheumatic Diseases|June 7, 2021
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypesMarialbert Acosta-Herrera, Martin Kerick, Elena Lopéz-Isac, et al.
Pageof 49